Similar articles for PMID: 18279462

Year	Number of Results
1914	1
1973	1
1988	1
1991	1
2000	1
2001	2
2003	1
2004	3
2005	9
2006	22
2007	24
2008	42
2009	27
2010	22
2011	11
2012	10
2013	12
2014	7
2015	3
2016	3
2017	1
2018	3
2019	1
2020	2
2024	0

1

QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy.

Desai N, Raste Y, Cooke NT, Harland CC. Desai N, et al. Br J Dermatol. 2008 May;158(5):1137-8. doi: 10.1111/j.1365-2133.2008.08457.x. Epub 2008 Feb 15. Br J Dermatol. 2008. PMID: 18279462 No abstract available.

2

The role of the QuantiFERON-TB Gold test as screening prior to administration of tumor necrosis factor inhibitors.

Martinez LC, Harrison-Balestra C, Caeiro JP, Nousari CH. Martinez LC, et al. Arch Dermatol. 2007 Jun;143(6):809-10. doi: 10.1001/archderm.143.6.809. Arch Dermatol. 2007. PMID: 17576961 No abstract available.

3

Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.

Girolomoni G, Abeni D. Girolomoni G, et al. Arch Dermatol. 2001 Jun;137(6):784-5. Arch Dermatol. 2001. PMID: 11405771 No abstract available.

4

Psoriasis exacerbation after a flu-like syndrome during anti-TNF-alpha therapy.

Cassano N, Coviello C, Loconsole F, Miracapillo A, Vena GA. Cassano N, et al. Eur J Dermatol. 2006 May-Jun;16(3):316-7. Eur J Dermatol. 2006. PMID: 16709508 No abstract available.

5

Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.

Chiu HY, Hsueh PR, Tsai TF. Chiu HY, et al. Br J Dermatol. 2011 Mar;164(3):553-9. doi: 10.1111/j.1365-2133.2010.10137.x. Epub 2011 Feb 17. Br J Dermatol. 2011. PMID: 21083541

6

Adolescent plaque psoriasis: our experience using etanercept.

Ruiz-Villaverde R, Sánchez-Cano D, Abalos-Medina G. Ruiz-Villaverde R, et al. J Eur Acad Dermatol Venereol. 2009 Aug;23(8):976-7. doi: 10.1111/j.1468-3083.2008.03081.x. Epub 2009 Jan 13. J Eur Acad Dermatol Venereol. 2009. PMID: 19207668 No abstract available.

7

Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.

Antoniou C, Dessinioti C, Stratigos A, Avgerinou G, Stavropoulos P, Katsambas A. Antoniou C, et al. J Eur Acad Dermatol Venereol. 2009 Aug;23(8):979-82. doi: 10.1111/j.1468-3083.2009.03093.x. J Eur Acad Dermatol Venereol. 2009. PMID: 19470056 No abstract available.

8

Ability to develop rhus allergic contact dermatitis in a patient with psoriasis receiving etanercept.

Myers W, Newman M, Katz B, Gottlieb AB. Myers W, et al. J Am Acad Dermatol. 2006 Nov;55(5 Suppl):S127-8. doi: 10.1016/j.jaad.2006.05.003. J Am Acad Dermatol. 2006. PMID: 17052536 No abstract available.

9

Safety of antitumour necrosis factor-α therapy in psoriatic patients with hepatitis B virus infection.

Nosotti L, Francesconi F, Izzi S, Berardesca E, Morrone A, Bonifati C. Nosotti L, et al. Br J Dermatol. 2010 Jun;162(6):1408-10. doi: 10.1111/j.1365-2133.2010.09714.x. Epub 2010 Feb 22. Br J Dermatol. 2010. PMID: 20184582 No abstract available.

10

Indeterminate results on the interferon-gamma release assay for tuberculosis screening should not be ignored.

Oon HH, Chong WS, Liew CF. Oon HH, et al. Br J Dermatol. 2008 Sep;159(4):992-3. doi: 10.1111/j.1365-2133.2008.08792.x. Br J Dermatol. 2008. PMID: 18717676 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

194 results

Results by year